AccScience Publishing / GTM / Volume 2 / Issue 1 / DOI: 10.36922/gtm.v2i1.67
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Inflammatory and anti-inflammatory responses in human T-lymphotropic virus Type 1 infection

Elnaz Sadat Hosseini1 Elham Abdollahi1,2* Nafiseh Saghafi1
Show Less
1 Supporting the Family and the Youth of Population Research Core, Department of Gynecology and Obstrict, Mashhad University of Medical Sciences, Mashhad, Iran
2 Immunology Research Center, Inflammation and Inflammatory Disease Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
Global Translational Medicine 2023, 2(1), 67
Submitted: 14 April 2022 | Accepted: 1 December 2022 | Published: 19 January 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Human T-lymphotropic virus Type 1 (HTLV-1) is a viral infectious agent that may cause chronic infection of T lymphocytes. HTLV-1 infection is related to multiple human diseases, including adult T-cell leukemia, which is a neoplastic growth of HTLV-1-infected T cells, and neoplastic inflammatory conditions such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), Sjögren’s syndrome, polymyositis uveitis, and bronchoalveolitis. T regulatory cells (Tregs), also known as regulatory T cells, and T helper 17 (Th17) cells, a distinct subset of cluster differentiation T cells with interleukin-17 as their major cytokine, orchestrate the pathogenesis of anti-inflammatory and inflammatory responses in HTLV-1-mediated diseases. In this review, we aim to evaluate the immune responses of Tregs as anti-inflammatory cells and Th17 cells as inflammatory cells in HTLV-1 infection.

Inflammatory responses
Anti-inflammatory responses
Human T-lymphotropic virus type 1
HTLV-1-associated myelopathy/tropical spastic paraparesis

Boostani R, Lotfinejad N, Zemorshidi F, et al., 2021, Planning and management to control and eliminate HTLV-1 infection in Iran. Iran J Basic Med Sci, 24: 264–266. 


Araya N, Sato T, Yagishita N, et al., 2011, Human T-lymphotropic virus Type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease. Viruses, 3: 1532–1548. 


Birmann BM, Breen EC, Stuver S, et al., 2009, Population differences in immune marker profiles associated with human T-lymphotropic virus Type I infection in Japan and Jamaica. Int J Cancer, 124: 614–621.


Tarokhian H, Rahimi H, Mosavat A, et al., 2018 HTLV- 1-host interactions on the development of adult T cell leukemia/lymphoma: Virus and host gene expressions. BMC Cancer, 18: 1287.


Carpentier A, Barez PY, Hamaidia M, et al., 2015, Modes of human T cell leukemia virus Type 1 transmission, replication and persistence. Viruses,7: 3603–3624. 


Nagate Y, Ezoe S, Fujita J, et al., 2021, Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia, 35: 107–118. 


Higuchi Y, Yasunaga JI, Mitagami Y, et al., 2020, HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. Proc Natl Acad Sci U S A, 117: 13740–13749.


Koyanagi Y, Itoyama Y, Nakamura N, et al., 1993, In vivo infection of human T-cell leukemia virus Type I in non-T cells. Virology, 196: 25–33.


Overbaugh J, Miller AD, Eiden MV, 2001, Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev, 65: 371–389.


Jones KS, Fugo K, Petrow-Sadowski C, et al., 2006, Human T-cell leukemia virus Type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J Virol, 80: 8291–8302.


Manel N, Kim FJ, Kinet S, et al., 2003, The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell, 115: 449–459. 


Mohammadi S, Abdollahi E, Nezamnia M, et al., 2021, Adoptive transfer of tregs: A novel strategy for cell-based immunotherapy in spontaneous abortion: Lessons from experimental models. Int Immunopharmacol, 90: 107195.


Quaresma JA, Yoshikawa GT, Koyama RV, et al., 2015, HTLV-1, immune response and autoimmunity. Viruses, 8: 5.


Lippi G, Lavie CJ, Sanchis-Gomar F, 2020, Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis, 63: 390–391.


Bhatla A, Mayer MM, Adusumalli S, et al., 2020, COVID-19 and cardiac arrhythmias. Heart Rhythm, 17: 1439–1444.


Eggenhuizen PJ, Ng BH, Ooi JD, 2020, Treg enhancing therapies to treat autoimmune diseases. Int J Mol Sci, 21: 7015.


Christoffersson G, von Herrath M, 2019, Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol, 40: 482–491. 


Romano M, Fanelli G, Albany CJ, et al., 2019, Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol, 10: 43. 


Bouwman W, Verhaegh W, Holtzer L, et al., 2020, Measurement of cellular immune response to viral infection and vaccination. Front Immunol, 11: 575074.


Jin Y, Wi HJ, Choi MH, et al., 2014, Regulation of anti-inflammatory cytokines IL-10 and TGF-β in mouse dendritic cells through treatment with Clonorchis sinensis crude antigen. Exp Mol Med, 46: e74.


Sanjabi S, Zenewicz LA, Kamanaka M, et al., 2009, Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol, 9: 447–453. 


Collison LW, Chaturvedi V, Henderson AL, et al., 2010, IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol, 11: 1093–1101. 


Sullivan JA, Tomita Y, Jankowska-Gan E, et al., 2020, Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance. Cell Rep, 30: 1039–1051. e5.


Shen P, Roch T, Lampropoulou V, et al., 2014, IL-35- producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature, 507: 366–370.


Veldhoen M, Hocking RJ, Atkins CJ, et al., 2006, TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 24: 179–189.


Konkel JE, Zhang D, Zanvit P, et al., 2017, Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses. Immunity, 46: 660–674.


Fujimoto Y, Kuramoto N, Yoneyama M, et al., 2020, Interleukin-19 as an immunoregulatory cytokine. Curr Mol Pharmacol, 14: 191–199.


Abdollahi E, Tavasolian F, Ghasemi N, et al., 2015, Association between lower frequency of R381Q variant (rs11209026) in IL-23 receptor gene and increased risk of recurrent spontaneous abortion (RSA). J Immunotoxicol, 12: 317–321.


Castro G, Liu X, Ngo K, et al., 2017, RORγt and RORα signature genes in human Th17 cells. PLoS One, 12: e0181868.


Park TY, Park SD, Cho JY, et al., 2014, RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells. Proc Natl Acad Sci U S A, 111: 18673–18678.


Chang D, Xing Q, Su Y, et al., 2020, The conserved non-coding sequences CNS6 and CNS9 control cytokine-induced rorc transcription during T helper 17 cell differentiation. Immunity, 53: 614–26. e4.


Ciofani M, Madar A, Galan C, et al., 2012, A validated regulatory network for Th17 cell specification. Cell, 151: 289–303.


Chi X, Jin W, Zhao X, et al., 2022, RORγt expression in mature TH17 cells safeguards their lineage specification by inhibiting conversion to TH2 cells. Sci Adv, 8: eabn7774. 


Neco HV, Teixeira VG, Trindade AC, et al., 2017, IL17A polymorphism is not associated with human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis. Viral Immunol, 30: 298–301.


Qu N, Xu M, Mizoguchi I, et al., 2013, Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol, 2013: 968549.


Wolk K, Witte E, Wallace E, et al., 2006, ILcke WD, Kunz S, Asadullah K, et al. cytokines, IL-17, IL-22, and IL-23, ise, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol, 36: 1309–1323. 


Chang SH, Dong C, 2009, IL-17F: Regulation, signaling and function in inflammation. Cytokine, 46: 7–11.


Kany S, Vollrath JT, Relja B, 2019, Cytokines in inflammatory disease. Int J Mol Sci, 20: 6008.


Hirano T, 2021, IL-6 in inflammation, autoimmunity and cancer. Int Immunol, 33: 127–148.


Martinez NE, Sato F, Kawai E, et al., 2012, Regulatory T cells and Th17 cells in viral infections: Implications for multiple sclerosis and myocarditis. Future Virol, 7: 593–608. 


Saghafi N, Rezaee SA, Momtazi-Borojeni AA, et al., 2022, The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19. Life Sci, 294: 120392.


Hamano R, Wu X, Wang Y, et al., 2015, Characterization of MT-2 cells as a human regulatory T cell-like cell line. Cell Mol Immunol, 12: 780–782.


Meissner ME, Mendonça LM, Zhang W, et al., 2017, Polymorphic nature of human T-cell leukemia virus Type 1 particle cores as revealed through characterization of a chronically infected cell line. J Virol, 91: e00369–e00317.


Satou Y, Yasunaga JI, Zhao T, et al., 2011, HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog, 7: e1001274.


Kchour G, Rezaee SR, Farid R, et al., 2013, The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology, 10: 91.


Swaims AY, Khani F, Zhang Y, et al., 2010, Immune activation induces immortalization of HTLV-1 LTR-tax transgenic CD4+ T cells. Blood, 116: 2994–3003. 


Champs AP, de Azeredo Passos VM, Carvalho G, et al., 2019, Cognitive impairment in HTLV-1-associated myelopathy, proviral load and inflammatory markers. Int J Infect Dis, 84: 121–126.


Guo K, Zhang X, 2021, Cytokines that modulate the differentiation of Th17 cells in autoimmune uveitis. J Immunol Res, 2021: 6693542.


Abdollahi E, Tavasolian F, Momtazi-Borojeni AA, et al., 2016, Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: A comprehensive review. J Immunotoxicol, 13: 286–300.


López-Abente J, Correa-Rocha R, Pion M, 2016, Functional mechanisms of treg in the context of HIV infection and the janus face of immune suppression. Front Immunol, 7: 192.


Yamano Y, Araya N, Sato T, et al., 2009, Abnormally high levels of virus-infected IFN-γ+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PloS One, 4: e6517.


Oh U, Grant C, Griffith C, et al., 2006, Reduced Foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus Type 1 Infection. J Infect Dis, 193: 1557–1566.


Satou Y, Matsuoka M, 2010, HTLV-1 and the host immune system: How the virus disrupts immune regulation, leading to HTLV-1 associated diseases. J Clin Exp Hematop, 50: 1–8.


Toulza F, Heaps A, Tanaka Y, et al., 2008, High frequency of CD4+ FoxP3+ cells in HTLV-1 infection: Inverse correlation with HTLV-1-specific CTL response. Blood, 111: 5047–5053.


Brito‐Melo G, Peruhype‐Magalhães V, Teixeira‐Carvalho A, et al., 2007, IL‐10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte‐derived TNF‐α and guarantee asymptomatic clinical status during chronic HTLV‐I infection. Clin Exp Immunol, 147: 35–44. 


De Sá KS, Santana BB, de Souza Ferreira TC, et al., 2016, IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy. Cytokine, 77: 79–87. 


Sasada A, Takaori-Kondo A, Shirakawa K, et al., 2005, APOBEC3G targets human T-cell leukemia virus Type 1. Retrovirology, 2: 32.


Best I, López G, Verdonck K, et al., 2009, IFN‐gamma production in response to tax 161-233, and frequency of CD4+ Foxp3+ and Lin-HLA‐DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV‐1‐carriers in a Peruvian population. Immunology, 128(1 Suppl): e777–e86.


Araújo AQ, Leite AC, Lima MA, et al., 2009, HTLV-1 and neurological conditions: When to suspect and when to order a diagnostic test for HTLV-1 infection? Arq Neuropsiquiatr, 67: 132–138. 


Castro-Costa CM, de Queiroz Campos Araújo A, Câmara CC, et al., 2009, Pain in tropical spastic paraparesis/ HTLV-I associated myelopathy patients. Arq Neuropsiquiatr, 67: 866–870.


Huang Q, Ling Z, Wang H, et al., 2022, Evaluation of the effects of 1, 25VitD3 on Th17 cells and Tregs in HTLV-1 infected cell lines. Acta Virol, 66: 127–138.


Nakao Y, Koizumi T, Matsui T, et al., 1987, Effect of 1α, 25-dihydroxyvitamin D3 on proliferation of activated T-cells and established human lymphotropic virus Type I-positive T-cell lines. J Natl Cancer Inst, 78: 1079–1086.


Reichel H, Koeffler HP, Norman AW, 1987, 25-Hydroxyvitamin D3 metabolism by human T-lymphotropic virus-transformed lymphocytes. J Clin Endocrinol Metab, 65: 519–526.


Koizumi T, Nakao Y, Kawanishi M, et al., 1989, Suppression of c T, Fujita T M, by human T-lymphotropic virus-transformed lymphocytes. hed huma. Int J Cancer, 44: 701–706.


Inoue D, Matsumoto T, Ogata E, et al., 1993, 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, Type I-infected T cells. J Biol Chem, 268: 16730–16736.


Elstner E, Lee Y, Hashiya M, et al., 1994, 1 alpha, 25-Dihydroxy-20-epi-Vitamin D3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood, 84: 1960–1967.


Peter SA, Cervantes JF, 1995, Hypercalcemia associated with adult T-cell leukemia/lymphoma (ATL). J Natl Med Assoc, 87: 746.


Masutani H, Ueda S, Yodoi J, 2005, The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ, 2: 991–998.

Conflict of interest
No conflicts of interest.
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Published by AccScience Publishing